AKTX vs. ELAB, MBRX, MIRA, ABVC, ERNA, IMNN, MTEM, GHSI, PPBT, and CMMB
Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Elevai Labs (ELAB), Moleculin Biotech (MBRX), MIRA Pharmaceuticals (MIRA), ABVC BioPharma (ABVC), Eterna Therapeutics (ERNA), Imunon (IMNN), Molecular Templates (MTEM), Guardion Health Sciences (GHSI), Purple Biotech (PPBT), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical preparations" industry.
Akari Therapeutics (NASDAQ:AKTX) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Akari Therapeutics had 2 more articles in the media than Elevai Labs. MarketBeat recorded 6 mentions for Akari Therapeutics and 4 mentions for Elevai Labs. Akari Therapeutics' average media sentiment score of 0.60 beat Elevai Labs' score of -0.03 indicating that Akari Therapeutics is being referred to more favorably in the media.
Akari Therapeutics received 262 more outperform votes than Elevai Labs when rated by MarketBeat users.
5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 22.2% of Elevai Labs shares are owned by institutional investors. 61.8% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Elevai Labs has higher revenue and earnings than Akari Therapeutics.
Summary
Akari Therapeutics beats Elevai Labs on 4 of the 7 factors compared between the two stocks.
Get Akari Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akari Therapeutics Competitors List
Related Companies and Tools
